Akili Interactive announced topline data from an open-label study (STARS-ADHD Adjunctive) of AKL-T01 for the treatment of attention deficit hyperactivity disorder in children with or without use of stimulants.
The Food and Drug Administration (FDA) has approved Dayvigo (lemborexant; Eisai) for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adult patients.
Patients exposed to a higher dose than expected may be at increased risk of sedation, agitation, increased reflexes, tremor, sweating, dilated pupils, gastrointestinal distress, nausea, constipation and more.
The Food and Drug Administration (FDA) has approved Caplyta (lumateperone; Intra-Cellular Therapies), an atypical antipsychotic, for the treatment of schizophrenia in adult patients.
The New Drug Application for viloxazine hydrochloride, a serotonin norepinephrine modulating agent, has been submitted to the FDA for the treatment of pediatric patients with ADHD.
The Food and Drug Administration (FDA) has granted Fast Track designation to BNC210 (Bionomics Limited) for the treatment of post-traumatic stress disorder (PTSD) and other trauma-related and stressor-related disorders.
The FDA has approved Secuado (asenapine; Noven) transdermal system for the treatment of adults with schizophrenia.
Nicotine mouth spray is currently approved as a smoking cessation aid in many countries outside the US.
The Food and Drug Administration (FDA) approved Wakix (pitolisant; Harmony Biosciences) for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy.
The FDA is warning consumers to stop using products known as Miracle or Master Mineral Solution, Miracle Mineral Supplement, MMS, Chlorine Dioxide Protocol, and Water Purification Solution due to numerous reports of significant health issues.
